3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Leukemia, Myeloid, Acute
32
Myelodysplastic Syndromes
28
Multiple Myeloma
27
Precursor Cell Lymphoblastic Leukemia-Lymphoma
26
Hodgkin Disease
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
11
Lymphoma, Non-Hodgkin
10
Lymphoma
10
Hematologic Neoplasms
10
Neuroblastoma
9
Myeloproliferative Disorders
9
Anemia, Refractory, with Excess of Blasts
8
Lymphoma, Mantle-Cell
7
Leukemia, Myelomonocytic, Chronic
7
Leukemia
7
Neoplasms, Plasma Cell
6
Lymphoma, T-Cell
6
Leukemia, Biphenotypic, Acute
6
Graft vs Host Disease
6
Leukemia, Lymphocytic, Chronic, B-Cell
5
Burkitt Lymphoma
5
Recurrence
4
Primary Myelofibrosis
4
Melanoma
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Leukemia, Myelomonocytic, Juvenile
4
Hematologic Diseases
4
Ganglioneuroblastoma
4
Anemia, Aplastic
4
Interventions
Vincristine
2
Etoposide
2
Carboplatin
2
Topotecan
1
Platinum Compounds
1
Melphalan
1
Lasers, Semiconductor
1
Lasers
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Eye Enucleation
1
Drug Therapy
1
Doxorubicin
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Retinal Neoplasms
×
Melphalan
×
1 year
×
Clear all
NCT02866136
2025-11-24
RETINO2011
Institut Curie
Phase 2
Active not recruiting
133 enrolled